Turning Point Therapeutics Stock Forecast, Price & News

Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions

Is Turning Point Therapeutics a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Turning Point Therapeutics stock.
View analyst ratings for Turning Point Therapeutics or view top-rated stocks.

How has Turning Point Therapeutics' stock price been impacted by COVID-19?

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TPTX stock has decreased by 11.6% and is now trading at $35.82.
View which stocks have been most impacted by COVID-19.

Are investors shorting Turning Point Therapeutics?

Turning Point Therapeutics saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 2,150,000 shares, a decrease of 22.9% from the October 31st total of 2,790,000 shares. Based on an average daily trading volume, of 439,100 shares, the short-interest ratio is currently 4.9 days. Currently, 5.0% of the shares of the stock are short sold.
View Turning Point Therapeutics' Short Interest.

When is Turning Point Therapeutics' next earnings date?

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Turning Point Therapeutics.

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) announced its quarterly earnings data on Tuesday, November, 9th. The company reported ($1.34) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by $0.08. The firm had revenue of $0.46 million for the quarter. During the same quarter in the previous year, the firm posted ($0.42) earnings per share.
View Turning Point Therapeutics' earnings history.

What price target have analysts set for TPTX?

9 equities research analysts have issued 12-month price targets for Turning Point Therapeutics' shares. Their forecasts range from $75.00 to $175.00. On average, they expect Turning Point Therapeutics' share price to reach $133.78 in the next year. This suggests a possible upside of 273.5% from the stock's current price.
View analysts' price targets for Turning Point Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Turning Point Therapeutics' key executives?

Turning Point Therapeutics' management team includes the following people:

• Athena Countouriotis, President, Chief Executive Officer & Director
• Miriam Cruz, Vice President-Clinical Operations
• Paolo Tombesi, Executive VP, Chief Financial & Accounting Officer
• Siegfried Reich, Chief Scientific Officer & Executive VP (LinkedIn Profile)
• Ed Gemo, Chief Information Officer & Senior Vice President

Who are some of Turning Point Therapeutics' key competitors?

Some companies that are related to Turning Point Therapeutics include Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Sarepta Therapeutics (SRPT), Biohaven Pharmaceutical (BHVN), Legend Biotech (LEGN), Zai Lab (ZLAB), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), Perrigo (PRGO), Mawson Infrastructure Group (WIZP), Cerevel Therapeutics (CERE), I-Mab (IMAB) and Allakos (ALLK).
View all of TPTX's competitors.

What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

When did Turning Point Therapeutics IPO?

(TPTX) raised $167 million in an initial public offering on Wednesday, April 17th 2019. The company issued 9,300,000 shares at $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Turning Point Therapeutics' stock symbol?

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Who are Turning Point Therapeutics' major shareholders?

Turning Point Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.59%), Wellington Management Group LLP (6.89%), Alliancebernstein L.P. (2.54%), Credit Suisse AG (1.75%), Geode Capital Management LLC (1.68%) and Goldman Sachs Group Inc. (1.46%). Company insiders that own Turning Point Therapeutics stock include Andrew John Partridge, Annette North, Athena Countouriotis, Brian Lee Baker, Jingrong Jean Cui, Mark J Alles, Mohammad Hirmand, Siegfried Reich and Yi Larson.
View institutional ownership trends for Turning Point Therapeutics.

Which major investors are selling Turning Point Therapeutics stock?

TPTX stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Alliancebernstein L.P., Two Sigma Investments LP, BlackRock Inc., Two Sigma Advisers LP, Sectoral Asset Management Inc, Frontier Capital Management Co. LLC, and Wellington Management Group LLP. Company insiders that have sold Turning Point Therapeutics company stock in the last year include Andrew John Partridge, Annette North, Athena Countouriotis, Brian Lee Baker, Mohammad Hirmand, Siegfried Reich, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics or view top insider-selling stocks.

Which major investors are buying Turning Point Therapeutics stock?

TPTX stock was bought by a variety of institutional investors in the last quarter, including Boxer Capital LLC, American Century Companies Inc., Allianz Asset Management GmbH, Geode Capital Management LLC, Altium Capital Management LP, Congress Asset Management Co. MA, Dimensional Fund Advisors LP, and SG Americas Securities LLC. Company insiders that have bought Turning Point Therapeutics stock in the last two years include Athena Countouriotis, and Mark J Alles.
View insider buying and selling activity for Turning Point Therapeutics or or view top insider-buying stocks.

How do I buy shares of Turning Point Therapeutics?

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Turning Point Therapeutics' stock price today?

One share of TPTX stock can currently be purchased for approximately $35.82.

How much money does Turning Point Therapeutics make?

Turning Point Therapeutics has a market capitalization of $1.77 billion and generates $25 million in revenue each year. The company earns $-157.29 million in net income (profit) each year or ($4.23) on an earnings per share basis.

How many employees does Turning Point Therapeutics have?

Turning Point Therapeutics employs 142 workers across the globe.

What is Turning Point Therapeutics' official website?

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

Where are Turning Point Therapeutics' headquarters?

Turning Point Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121.

How can I contact Turning Point Therapeutics?

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at (858) 926-5251 or via email at [email protected].